Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Benitec Biopharma (BNTC) over the last 5 years, with Q1 2025 value amounting to $38.6 million.

  • Benitec Biopharma's Shares Outstanding (Diluted Average) rose 11113.48% to $38.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $38.6 million, marking a year-over-year increase of 11113.48%. This contributed to the annual value of $18.4 million for FY2024, which is 122516.58% up from last year.
  • According to the latest figures from Q1 2025, Benitec Biopharma's Shares Outstanding (Diluted Average) is $38.6 million, which was up 11113.48% from $37.3 million recorded in Q4 2024.
  • In the past 5 years, Benitec Biopharma's Shares Outstanding (Diluted Average) registered a high of $38.6 million during Q1 2025, and its lowest value of $480688.0 during Q2 2022.
  • In the last 5 years, Benitec Biopharma's Shares Outstanding (Diluted Average) had a median value of $6.2 million in 2021 and averaged $11.2 million.
  • In the last 5 years, Benitec Biopharma's Shares Outstanding (Diluted Average) crashed by 9218.56% in 2022 and then soared by 134603.34% in 2024.
  • Benitec Biopharma's Shares Outstanding (Diluted Average) (Quarter) stood at $8.2 million in 2021, then crashed by 80.16% to $1.6 million in 2022, then soared by 58.91% to $2.6 million in 2023, then skyrocketed by 1346.03% to $37.3 million in 2024, then grew by 3.61% to $38.6 million in 2025.
  • Its last three reported values are $38.6 million in Q1 2025, $37.3 million for Q4 2024, and $27.9 million during Q3 2024.